77 results on '"Oze, T."'
Search Results
2. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin
- Author
-
Harada, N., Hiramatsu, N., Oze, T., Morishita, N., Yamada, R., Hikita, H., Miyazaki, M., Yakushijin, T., Miyagi, T., Yoshida, Y., Tatsumi, T., Kanto, T., Kasahara, A., Oshita, M., Mita, E., Hagiwara, H., Inui, Y., Katayama, K., Tamura, S., Yoshihara, H., Imai, Y., Inoue, A., Hayashi, N., and Takehara, T.
- Published
- 2014
- Full Text
- View/download PDF
3. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
- Author
-
Inoue, Y., Hiramatsu, N., Oze, T., Yakushijin, T., Mochizuki, K., Hagiwara, H., Oshita, M., Mita, E., Fukui, H., Inada, M., Tamura, S., Yoshihara, H., Hayashi, E., Inoue, A., Imai, Y., Kato, M., Miyagi, T., Hohsui, A., Ishida, H., Kiso, S., Kanto, T., Kasahara, A., Takehara, T., and Hayashi, N.
- Published
- 2010
- Full Text
- View/download PDF
4. Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin
- Author
-
Oze, T., Hiramatsu, N., Uakushijin, T., Kurokawa, M., Igura, T., Mochizuki, K., Imanaka, K., Yamada, A., Oshita, M., Hagiwara, H., Mita, E., Ito, T., Inui, Y., Hijioka, T., Tamura, S., Yoshihara, H., Hayashi, E., Inoue, A., Imai, Y., Kato, M., Yoshida, Y., Tatsumi, T., Ohkawa, K., Kiso, S., Kanto, T., Kasahara, A., Takehara, T., and Hayashi, N.
- Published
- 2009
- Full Text
- View/download PDF
5. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin
- Author
-
Hiramatsu, N., Oze, T., Yakushijin, T., Inoue, Y., Igura, T., Mochizuki, K., Imanaka, K., Kaneko, A., Oshita, M., Hagiwara, H., Mita, E., Nagase, T., Ito, T., Inui, Y., Hijioka, T., Katayama, K., Tamura, S., Yoshihara, H., Imai, Y., Kato, M., Yoshida, Y., Tatsumi, T., Ohkawa, K., Kiso, S., Kanto, T., Kasahara, A., Takehara, T., and Hayashi, N.
- Published
- 2009
- Full Text
- View/download PDF
6. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1
- Author
-
Oze, T., primary, Hiramatsu, N., additional, Yakushijin, T., additional, Yamada, R., additional, Harada, N., additional, Morishita, N., additional, Oshita, M., additional, Mita, E., additional, Ito, T., additional, Inui, Y., additional, Inada, M., additional, Tamura, S., additional, Yoshihara, H., additional, Imai, Y., additional, Kato, M., additional, Miyagi, T., additional, Yoshida, Y., additional, Tatsumi, T., additional, Kasahara, A., additional, Hayashi, N., additional, and Takehara, T., additional
- Published
- 2014
- Full Text
- View/download PDF
7. P1049 RISK FACTORS FOR HEPATOCELLULAR CARCINOMA AMONG PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ENTECAVIR
- Author
-
Yamada, R., primary, Hiramatsu, N., additional, Morishita, N., additional, Harada, N., additional, Oze, T., additional, Yakushijin, T., additional, Miyagi, T., additional, Yoshida, Y., additional, Tatsumi, T., additional, Ohkawa, K., additional, Kasahara, A., additional, Mita, E., additional, Hagiwara, H., additional, Oshita, M., additional, Itoh, T., additional, Hijioka, T., additional, Yoshihara, H., additional, Imai, Y., additional, Hayashi, N., additional, and Takehara, T., additional
- Published
- 2014
- Full Text
- View/download PDF
8. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin
- Author
-
Harada, N., primary, Hiramatsu, N., additional, Oze, T., additional, Morishita, N., additional, Yamada, R., additional, Hikita, H., additional, Miyazaki, M., additional, Yakushijin, T., additional, Miyagi, T., additional, Yoshida, Y., additional, Tatsumi, T., additional, Kanto, T., additional, Kasahara, A., additional, Oshita, M., additional, Mita, E., additional, Hagiwara, H., additional, Inui, Y., additional, Katayama, K., additional, Tamura, S., additional, Yoshihara, H., additional, Imai, Y., additional, Inoue, A., additional, Hayashi, N., additional, and Takehara, T., additional
- Published
- 2013
- Full Text
- View/download PDF
9. 333 THE USEFULLNESS OF VS/PLT: A NEW MARKER OF LIVER FIBROSIS
- Author
-
Song, C., primary, Hiramatsu, N., additional, Oze, T., additional, Yamada, R., additional, Inoue, Y., additional, Kurokawa, M., additional, Yakushijin, T., additional, Mochizuki, K., additional, Kiso, S., additional, Kanto, T., additional, Kasahara, A., additional, Takehara, T., additional, and Hayashi, N., additional
- Published
- 2011
- Full Text
- View/download PDF
10. Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection
- Author
-
YAKUSHIJIN, T, primary, KANTO, T, additional, INOUE, M, additional, OZE, T, additional, MIYAZAKI, M, additional, ITOSE, I, additional, MIYATAKE, H, additional, SAKAKIBARA, M, additional, KUZUSHITA, N, additional, and HIRAMATSU, N, additional
- Published
- 2006
- Full Text
- View/download PDF
11. Effect of orthodontic brackets and different wires on radiofrequency heating and magnetic field interactions during 3-T MRI.
- Author
-
Görgülü, S., Ayyılddız, S., Kamburoğlu, K., Gökçe, S., and Oze, T.
- Subjects
MAGNETIC fields ,RADIO frequency ,ORTHODONTICS ,MAGNETIC resonance imaging ,DENTAL implants ,DENTAL extraction ,BIOLOGICAL specimens ,STAINLESS steel - Abstract
Objectives: To evaluate the heating and magnetic field interactions of fixed orthodontic appliances with different wires and ligaments in a 3-T MRI environment and to estimate the safety of these orthodontic materials. Methods: 40 non-carious extracted human maxillary teeth were embedded in polyvinyl chloride boxes, and orthodontic brackets were bonded. Nickel-titanium and stainless steel arch wires, and elastic and stainless steel ligaments were used to obtain four experimental groups in total. Specimens were evaluated at 3 T for radiofrequency heating and magnetic field interactions. Radiofrequency heating was evaluated by placing specimens in a cylindrical plastic container filled with isotonic solution and measuring changes in temperature after T
1 weighted axial sequencing and after completion of all sequences. Translational attraction and torque values of specimens were also evaluated. One-way ANOVA test was used to compare continuous variables of temperature change. Significance was set at p < 0.05. Results: None of the groups exhibited excessive heating (highest temperature change: <3.04 °C), with the maximum increase in temperature observed at the end of the T1 weighted axial sequence. Magnetic field interactions changed depending on the material used. Although the brackets presented minor interactions that would not cause movement in situ, nickel titanium and stainless steel wires presented great interactions that may pose a risk for the patient. Conclusions: The temperature changes of the specimens were considered to be within acceptable ranges. With regard to magnetic field interactions, brackets can be considered "MR safe"; however, it would be safe to replace the wires before MRI. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
12. Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.
- Author
-
Kanto T, Inoue M, Oze T, Miyazaki M, Sakakibara M, Kakita N, Matsubara T, Higashitani K, Hagiwara H, Iio S, Katayama K, Mita E, Kasahara A, Hiramatsu N, Takehara T, Hayashi N, Kanto, Tatsuya, Inoue, Michiyo, Oze, Tsugiko, and Miyazaki, Masanori
- Abstract
Background: For the treatment of chronic hepatitis C, a combination of pegylated interferon-α (PEG-IFNα) and ribavirin has been widely used as a standard of care. Enhancement of immune response against hepatitis C virus (HCV) is known to be involved in the efficacy of the combination therapy. Our aim was to elucidate whether or not the frequency or function of blood cells is related to the outcome of the therapy.Methods: Sixty-seven chronic hepatitis C patients with high viral load of HCV genotype 1 infection who underwent 48 weeks of PEG-IFNα2b and ribavirin therapy were examined. During the treatment, frequencies of myeloid or plasmacytoid dendritic cells, Th1, Th2 cells, NK cells, and regulatory T cells were phenotypically determined.Results: Among the patients enrolled, 29 showed a sustained virological response (SVR), 18 a transient response (TR) and 17 no response (NR). The clinical and immunological markers were compared between the SVR and non-SVR patients, including TR and NR. Based on clinical, histological, immunological parameters, and cumulative dosage of PEG-IFNα2b and ribavirin, multivariate analyses revealed that higher platelet counts and higher regulatory T cell frequency at week 12 are indicative of SVR. Even in patients who attained complete early virological response at week 12, multivariate analyses disclosed that higher platelet counts and higher plasmacytoid dendritic cell frequency are indicative of SVR.Conclusions: In PEG-IFNα and ribavirin combination therapy for chronic hepatitis C patients, the increments of regulatory T cells and plasmacytoid dendritic cell frequency are independently related to favorable virological response to the therapy. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
13. A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution.
- Author
-
Toyama T, Hiramatsu N, Yakushijin T, Oze T, Nakanishi F, Yasumaru M, Mochizuki K, Kanto T, Takehara T, Kasahara A, and Hayashi N
- Published
- 2008
- Full Text
- View/download PDF
14. Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
- Author
-
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, and Takehara T
- Subjects
- Humans, Aged, Bevacizumab adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy
- Abstract
The treatment efficiency and predictors of atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma in real-world practice have not been established. This study aimed to assess the efficacy and safety of atezolizumab plus bevacizumab and to investigate predictors of progression-free survival and overall survival. Patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy in 19 hospitals were enrolled before treatment and observed prospectively. The outcomes of 222 patients in this cohort were analyzed. The objective response rate and disease control rate were 22.0% and 70.6%, respectively, whereas the median progression-free survival was 5.7 months. Independent risk factors for shortened progression-free survival were younger age (<75 years; 3.9 months vs. 8.6 months), higher number of intrahepatic tumors (≥5; 4.0 months vs. 7.9 months), macrovascular invasion (2.3 months vs. 6.7 months), and higher neutrophil-to-lymphocyte ratio (≥3.03; 3.0 months vs. 7.8 months). The median overall survival was not reached; however, independent risk factors for shortened overall survival were absence of hyperlipidemia, higher number of intrahepatic tumors (≥5), macrovascular invasion, higher α-fetoprotein level (≥400 ng/mL), worse Child-Pugh score (≥6), and higher neutrophil-to-lymphocyte ratio (≥3.03). Severe adverse events (grade ≥3) were observed in 96 patients (36.0%), with proteinuria being the most frequent. In conclusion, patients with older age, lower number of intrahepatic tumors, absent macrovascular invasion, and lower neutrophil-to-lymphocyte ratio are expected to have better progression-free survival with atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Tetsuo Takehara has received lecture fees and research grants from Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd. Takahiro Kodama has received lecture fees from Chugai Pharmaceutical Co., Ltd and AstraZeneca K.K. All other authors declare no conflicts of interest., (Copyright: © 2024 Kai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
15. Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.
- Author
-
Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, and Takehara T
- Abstract
Aim: In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors of HCC in patients with an SVR achieved from interferon treatment changed. Methods Among patients prospectively registered for pegylated interferon and ribavirin treatment, 2021 with an SVR without HCC development during the treatment period were followed up. The mean observation period was 49.5 ± 26.2 months., Results: The multivariable Cox regression analysis showed that older age, diabetes mellitus, advanced liver disease, and higher post-treatment AFP level were the independent risk factors throughout the observation period. The annual occurrence rate of HCC was 0.74% in the third year, 0.54% in the fourth year, and 0.40% in the fifth year; it gradually decreased from the third year. Because the time course hazards for HCC changed at 48 months, we separately analyzed its risk factors before and after this change point. The multivariable Cox regression analysis showed that the four above-mentioned factors were significantly related to HCC development within 4 years. Conversely, the univariable Cox regression analysis only identified diabetes mellitus as a significant factor for HCC development after 4 years., Conclusion: The frequency of HCC in hepatitis C patients who achieved an SVR from interferon treatment decreased during the observation period, and its risk factors changed between the early and late periods., (© 2019 The Japan Society of Hepatology.)
- Published
- 2019
- Full Text
- View/download PDF
16. Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.
- Author
-
Morishita N, Hiramatsu N, Oze T, Urabe A, Tahata Y, Yamada R, Yakushijin T, Hosui A, Iio S, Yamada A, Hagiwara H, Mita E, Yamada Y, Ito T, Inada M, Katayama K, Yabuuchi I, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, and Takehara T
- Abstract
Aim: Simeprevir (SMV)-based triple therapy is an effective retreatment option following failure of telaprevir (TVR)-based triple therapy. However, it is unclear whether the persistence of resistance-associated variants (RAVs) induced by TVR-based therapy may reduce the treatment effect of SMV-based therapy., Methods: The factors associated with the treatment effect, including RAVs in the NS3 region, were examined in 21 patients with genotype 1b HCV infection who were treated with SMV-based therapy after failure of TVR-based therapy. Ultra-deep sequencing was carried out to detect RAVs., Results: With the exception of one patient who discontinued treatment owing to adverse events, the sustained virologic response (SVR) rate was 50% (10/20). Ultra-deep sequencing at the start of SMV-based therapy revealed that TVR-resistant variants were detected in six patients (29%), and no variants were observed at position 168. Cross-resistance between TVR and SMV with low frequency was detected in only one patient, and this patient achieved SVR. Higher SVRs for SMV-based therapy were attained in patients who discontinued treatment owing to the adverse effects of prior TVR-based therapy (discontinuation 100% vs. non-discontinuation 29%, P = 0.005), and patients who relapsed following prior pegylated interferon plus ribavirin therapy (relapse 100% vs. non-response 20%, P = 0.007)., Conclusions: In this study, ultra-deep sequencing analysis revealed that TVR and/or SMV-resistant variants may have no influence on the effect of SMV-based therapy after failure of TVR-based therapy. Patients who discontinued treatment owing to adverse effects of TVR-based therapy and relapsers to previous pegylated interferon/ribavirin therapy would be good candidates for retreatment with SMV-based therapy., (© 2016 The Japan Society of Hepatology.)
- Published
- 2017
- Full Text
- View/download PDF
17. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
- Author
-
Kai Y, Hikita H, Morishita N, Murai K, Nakabori T, Iio S, Hagiwara H, Imai Y, Tamura S, Tsutsui S, Naito M, Nishiuchi M, Kondo Y, Kato T, Suemizu H, Yamada R, Oze T, Yakushijin T, Hiramatsu N, Sakamori R, Tatsumi T, and Takehara T
- Subjects
- Animals, Anti-Retroviral Agents pharmacology, Carbamates, Evolution, Molecular, Hepacivirus classification, Hepacivirus drug effects, Hepatitis C drug therapy, Hepatitis C virology, Humans, Imidazoles pharmacology, Imidazoles therapeutic use, Isoquinolines pharmacology, Isoquinolines therapeutic use, Mice, Phylogeny, Pyrrolidines, Selection, Genetic, Sulfonamides pharmacology, Sulfonamides therapeutic use, Valine analogs & derivatives, Drug Resistance, Viral genetics, Hepacivirus genetics, Mutation
- Abstract
Resistance-associated substitutions (RASs) in hepatitis C virus (HCV) appear upon failure of treatment with direct-acting antivirals (DAAs). However, their origin has not been clarified in detail. Among 11 HCV genotype 1b patients who experienced virologic failure with asunaprevir (ASV)/daclatasvir (DCV), 10 had major NS5A L31M/V-Y93H variants after treatment. L31M/V-Y93H variants were detected as a minor clone before therapy in 6 patients and were the most closely related to the post-treatment variants by phylogenetic tree analysis in 4 patients. Next, to consider the involvement of a trace amount of pre-existing variants below the detection limit, we analysed human hepatocyte chimeric mice infected with DAA-naïve patient serum. L31V-Y93H variants emerged after treatment with ledipasvir (LDV)/GS-558093 (nucleotide NS5B inhibitor) and decreased under the detection limit, but these variants were dissimilar to the L31V-Y93H variants reappearing after ASV/DCV re-treatment. Finally, to develop an infection derived from a single HCV clone, we intrahepatically injected full-genome HCV RNA (engineered based on the wild-type genotype 1b sequence) into chimeric mice. A new Y93H mutation actually occurred in this model after LDV monotherapy failure. In conclusion, post-treatment RASs appear by 2 mechanisms: the selection of pre-existing substitutions among quasispecies and the generation of novel mutations during therapy.
- Published
- 2017
- Full Text
- View/download PDF
18. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
- Author
-
Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Hosui A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Yamada Y, Inada M, Katayama K, Tamura S, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, and Takehara T
- Subjects
- Aged, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Humans, Interferon-alpha therapeutic use, Interferons, Interleukins genetics, Male, Middle Aged, Polyethylene Glycols therapeutic use, Polymorphism, Single Nucleotide, Pyrophosphatases genetics, Recombinant Proteins administration & dosage, Recombinant Proteins therapeutic use, Ribavirin adverse effects, Ribavirin therapeutic use, Simeprevir therapeutic use, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Polyethylene Glycols administration & dosage, Ribavirin administration & dosage, Simeprevir administration & dosage, Sustained Virologic Response
- Abstract
The factors associated with sustained virologic response (SVR) in chronic hepatitis C (CH-C) genotype 1 patients treated with simeprevir (SMV), pegylated interferon (Peg-IFN) plus ribavirin (RBV) triple therapy have not been fully investigated. Two hundred and twenty-nine treatment-naïve CH-C patients treated with SMV triple therapy were enrolled in this study. The overall SVR rate was 87% in per-protocol analysis. In multivariate analysis, the interleukin (IL) 28B genotype (rs8099917, TT vs. non-TT, odds ratio [OR]: 0.044, P = 0.001) and RBV dose (< 10/10-12/ ≥ 12 mg/kg/day, OR: 4.513, P = 0.041) were significant factors associated with SVR. In patients with the IL28B non-TT genotype, RBV dose affected SVR dose-dependently in stratified analysis of RBV dose (P = 0.015); it was 44% (8/18) for patients administered <10 mg/kg/day of RBV, 78% (14/18) for those administered 10-12 mg/kg/day of RBV, and 100% (3/3) for those administered ≥12 mg/kg/day of RBV, whereas in patients with the IL28B TT genotype, a significant correlation between SVR and RBV dose was not observed (P = 0.229). Regarding RBV dose reduction of less than 10 mg/kg/day, the inosine triphosphate pyrophosphatase (ITPA) genotype (rs1127354, CC vs. non-CC, OR: 0.239, P = 0.003) and age (by 1 y.o., OR: 1.084, P = 0.002) were significant independent factors. RBV dosage affected SVR dose-dependently in patients with the IL28B non-TT genotype treated with SMV triple therapy. Special attention to anemia progression and RBV dosage should be paid to aged patients with the ITPA CC genotype. J. Med. Virol. 88:1776-1784, 2016. © 2016 Wiley Periodicals, Inc., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
19. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
- Author
-
Tahata Y, Hiramatsu N, Oze T, Morishita N, Harada N, Yamada R, Yakushijin T, Mita E, Hagiwara H, Yamada Y, Ito T, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Irishio K, Kato M, Hikita H, Sakamori R, Miyagi T, Yoshida Y, Tatsumi T, Hamasaki T, Hayashi N, and Takehara T
- Subjects
- Aged, Antiviral Agents therapeutic use, Bilirubin blood, Drug Therapy, Combination, Female, Genotype, Hemoglobins metabolism, Hepatitis C, Chronic blood, Humans, Hyperbilirubinemia blood, Hyperbilirubinemia chemically induced, Interferon alpha-2, Interferon-alpha adverse effects, Interferon-alpha therapeutic use, Male, Middle Aged, Polyethylene Glycols adverse effects, Polyethylene Glycols therapeutic use, Prospective Studies, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Ribavirin adverse effects, Ribavirin therapeutic use, Risk Factors, Simeprevir adverse effects, Simeprevir therapeutic use, Treatment Outcome, Antiviral Agents adverse effects, Hepatitis C, Chronic drug therapy, Hyperbilirubinemia genetics, Pyrophosphatases genetics
- Abstract
Background: Hyperbilirubinemia, mild or moderate, is a commonly observed laboratory abnormality in chronic hepatitis C patients treated with simeprevir with pegylated interferon (Peg-IFN) plus ribavirin. In this prospective, multicenter study, we aimed to investigate the clinical features and factors associated with bilirubin increases during the therapy., Methods: A total of 192 patients with chronic hepatitis C who were treated with simeprevir with Peg-IFN plus ribavirin were analyzed., Results: The mean serum bilirubin level increased significantly during the initial 12 weeks of simeprevir administration and peaked at 2 weeks after the administration. Hyperbilirubinemia of more than 2 mg/dl developed in 18% of the patients; in 85% of those patients, the bilirubin levels peaked within 6 weeks and gradually decreased thereafter. A univariable analysis revealed that an increase in serum total bilirubin of 1.0 mg/dl or more from baseline was significantly associated with the sex, red blood cell count, serum hemoglobin level, serum alanine aminotransferase level, serum creatinine level and inosine triphosphate pyrophosphatase (ITPA) genotype. In the multivariable analysis, the ITPA genotype (CC odds ratio 4.990, p = 0.011) was found to be the only independent factor. Consistent with this result, there was a significant correlation between hyperbilirubinemia and the degree of hemolytic anemia., Conclusions: Hyperbilirubinemia develops at early time points after simeprevir administration in most cases and is dependent on the ITPA genotype. Careful attention should be paid to hyperbilirubinemia, which occurs at later time points or in patients with an ITPA non-CC genotype so that a diagnosis of liver damage with hyperbilirubinemia is not missed.
- Published
- 2016
- Full Text
- View/download PDF
20. [Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C].
- Author
-
Hiramatsu N and Oze T
- Subjects
- Drug Combinations, Genotype, Hepacivirus drug effects, Hepacivirus genetics, Humans, Treatment Outcome, Hepatitis C, Chronic drug therapy, Interferons therapeutic use, Ribavirin therapeutic use
- Published
- 2015
21. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
- Author
-
Kai Y, Hikita H, Tatsumi T, Nakabori T, Saito Y, Morishita N, Tanaka S, Nawa T, Oze T, Sakamori R, Yakushijin T, Hiramatsu N, Suemizu H, and Takehara T
- Subjects
- Animals, Antiviral Agents therapeutic use, Benzimidazoles therapeutic use, Carbamates, Drug Combinations, Female, Fluorenes therapeutic use, Hepacivirus drug effects, Hepatitis C, Chronic virology, Hepatitis, Viral, Animal virology, Hepatocytes virology, Humans, Imidazoles therapeutic use, Isoquinolines therapeutic use, Male, Middle Aged, Pyrrolidines, Sofosbuvir therapeutic use, Sulfonamides therapeutic use, Transplantation Chimera, Treatment Failure, Valine analogs & derivatives, Drug Resistance, Multiple, Viral genetics, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Hepatitis, Viral, Animal drug therapy
- Abstract
Background: Resistance-associated variants (RAVs) emerge at multiple positions spanning hepatitis C virus (HCV) NS3/4A and NS5A regions upon failure of asunaprevir/daclatasvir combination therapy. It has not been determined whether the emergence of such RAVs have an impact on re-treatment by a combination of ledipasvir and sofosbuvir, a potent regimen for HCV genotype 1 infection., Methods: TK-NOG human hepatocyte chimeric mice were inoculated with sera from a patient with treatment failure of asunaprevir/daclatasvir therapy., Results: They developed persistent HCV infection with triple variants of NS3/4A D168V, NS5A L31V plus Y93H. Administration of ledipasvir/GS-558093 (a NS5B nucleotide analog) in these mice failed to achieve end-of-treatment response or sustained virologic response, which was in sharp contrast to the results in mice with wild-type virus infection. The administration of telaprevir/GS-558093 successfully achieved it in those mice., Conclusions: Treatment failure with asunaprevir/daclatasvir may limit further treatment options. This population may represent a growing unmet medical need.
- Published
- 2015
- Full Text
- View/download PDF
22. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
- Author
-
Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, and Takehara T
- Subjects
- Aged, Antiviral Agents administration & dosage, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular therapy, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Hepatitis C, Chronic complications, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Liver Neoplasms diagnosis, Liver Neoplasms etiology, Liver Neoplasms therapy, Male, Middle Aged, Neoplasm Recurrence, Local, Polyethylene Glycols administration & dosage, Recombinant Proteins administration & dosage, Recombinant Proteins therapeutic use, Retrospective Studies, Ribavirin administration & dosage, Risk Factors, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
The use of pegylated interferon (Peg-IFN) plus ribavirin combination therapy for chronic hepatitis C patients who received curative treatment for hepatocellular carcinoma is controversial. This study tried to clarify this. Ninety-nine chronic hepatitis C patients who received curative resection or radiofrequency ablation for primary hepatocellular carcinoma, met the Milan criteria and were treated with Peg-IFN plus ribavirin therapy were enrolled (75 males, 24 females; mean age, 65.0 ± 5.9 years; 79 HCV genotype 1, 20 genotype 2). Among them, 40 patients who had received curative treatment for a single carcinoma were analyzed for recurrence (observation period: 27.6 ± 18.1 months). The factors associated with recurrence were examined using a log-rank test and a Cox proportional-hazards model. The discontinuation rate of the Peg-IFN plus ribavirin combination therapy was 25% (25/99). Among the patients who completed the therapy, the sustained virologic response rates were 35% for the genotype 1 patients and 56% for the genotype 2 patients. The cumulative incidence rates of recurrence were 10.0% at 1 year and 40.8% at 3 years. On multivariate analysis, a virologic response and platelet counts served as independent factors of recurrence (sustained virologic response, hazard ratio = 0.190, P = 0.029; platelet counts <12 × 10(4) /mm(3), hazard ratio = 3.19, P = 0.019). It is concluded that patients with chronic hepatitis C virus infection after curative treatment for hepatocellular carcinoma can be candidates for anti-viral therapy to reduce the recurrence of hepatocellular carcinoma, especially patients with low platelet counts., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
23. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
- Author
-
Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, and Takehara T
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents therapeutic use, Biomarkers, Tumor blood, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular etiology, Female, Follow-Up Studies, Guanine therapeutic use, Hepatitis B, Chronic complications, Humans, Incidence, Japan epidemiology, Liver Neoplasms epidemiology, Liver Neoplasms etiology, Male, Middle Aged, Retrospective Studies, Risk Factors, Young Adult, Carcinoma, Hepatocellular blood, Guanine analogs & derivatives, Hepatitis B, Chronic drug therapy, Liver Neoplasms blood, alpha-Fetoproteins metabolism
- Abstract
Background: Entecavir (ETV) is one of the first-line nucleoside analogs for treating patients with chronic hepatitis B virus (HBV) infection. However, the hepatocellular carcinoma (HCC) risk for ETV-treated patients remains unclear., Methods: A total of 496 Japanese patients with chronic HBV infection undergoing ETV treatment were enrolled in this study. The baseline characteristics were as follows: age 52.6 ± 12.0 years, males 58%, positive for hepatitis B e antigen 45 %, cirrhosis 19%, and median HBV DNA level 6.9 log copies (LC) per milliliter. The mean treatment duration was 49.9 ± 17.5 months., Results: The proportions of HBV DNA negativity (below 2.6 LC/mL) were 68% at 24 weeks and 86% at 1 year, and the rates of alanine aminotransferase (ALT) level normalization were 62 and 72%, respectively. The mean serum alpha-fetoprotein (AFP) levels decreased significantly at 24 weeks after ETV treatment initiation (from 29.0 ± 137.1 to 5.7 ± 27.9 ng/mL, p < 0.001). The cumulative incidence of HCC at 3, 5, and 7 years was 6.0, 9.6, and 17.2%, respectively, among all enrolled patients. In a multivariate analysis, advanced age [55 years or older, hazard ratio (HR) 2.84; p = 0.018], cirrhosis (HR 5.59, p < 0.001), and a higher AFP level (10 ng/mL or greater) at 24 weeks (HR 2.38, p = 0.034) were independent risk factors for HCC incidence. HCC incidence was not affected by HBV DNA negativity or by ALT level normalization at 24 weeks., Conclusions: The AFP level at 24 weeks after ETV treatment initiation can be the on-treatment predictive factor for HCC incidence among patients with chronic HBV infection.
- Published
- 2015
- Full Text
- View/download PDF
24. Erratum to: Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis.
- Author
-
Morishita N, Hiramatsu N, Oze T, Harada N, Yamada R, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, and Takehara T
- Published
- 2015
- Full Text
- View/download PDF
25. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Yamada A, Oshita M, Kaneko A, Suzuki K, Inui Y, Tamura S, Yoshihara H, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, and Takehara T
- Subjects
- Aged, Anemia chemically induced, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Dose-Response Relationship, Drug, Drug Eruptions etiology, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Hepacivirus isolation & purification, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferon-alpha adverse effects, Male, Middle Aged, Oligopeptides adverse effects, Oligopeptides therapeutic use, Polyethylene Glycols adverse effects, Prospective Studies, RNA, Viral blood, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Ribavirin adverse effects, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha therapeutic use, Oligopeptides administration & dosage, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
Background: Triple therapy with telaprevir (TVR), pegylated interferon and ribavirin has improved antiviral efficacy in patients with chronic hepatitis C (CH-C). However, the severe adverse effects caused by TVR are important to resolve. In this prospective, randomized, multicenter, open-label study, the antiviral efficacy and safety in the reduced administration of TVR were examined., Methods: A total of 81 CH-C Japanese patients with HCV genotype 1 were randomized into two regimens of TVR 2250 mg (TVR-2250) or 1500 mg (TVR-1500) and treated with triple therapy for 24 weeks., Results: The mean HCV RNA at start, 2 and 4 weeks of treatment were 6.69 ± 0.70, 1.05 ± 0.74, 0.22 ± 0.48 log10 IU/ml in the TVR-2250 group and 6.70 ± 0.62, 1.02 ± 0.62, 0.13 ± 0.41 log10 IU/ml in the TVR-1500 group. The SVR rates were 85% in both groups (35/41 and 34/40, respectively). There were no patients with viral breakthrough in either group. As for adverse effects, rash more than moderate and severe anemia with <8.5 g/dl of hemoglobin were higher in the TVR-2250 group than in the TVR-1500 group (p = 0.046, p < 0.001, respectively). The increase in serum creatinine levels and decrease in estimated glomerular filtration rates were higher in the TVR-2250 group than in the TVR-1500 group., Conclusions: The lower dose of TVR (1500 mg/day) can result in similar SVR rates and lower treatment-related adverse effects compared to the higher dose of TVR (2250 mg/day) in triple therapy (UMIN: 000007313, 000007330).
- Published
- 2015
- Full Text
- View/download PDF
26. [Pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C].
- Author
-
Oze T, Hiramatsu N, and Takehara T
- Subjects
- Drug Therapy, Combination, Humans, Liver Neoplasms prevention & control, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Ribavirin administration & dosage
- Abstract
The antiviral therapy for patients with chronic hepatitis C virus(HCV) infection has changed from interferon(IFN) monotherapy to dual therapy with IFN plus ribavirin(RBV), moreover pegylated IFN(Peg-IFN) plus RBV. The sustained virologic response(SVR), defined as HCV RNA negativiation at 24 weeks after the treatment, were obtained 50% among the patients with genotype 1 (48 weeks treatment) and 80% among those with genotype 2 (24 weeks treatment) in Peg-IFN plus RBV combination therapy. The baseline host factors such as age, the degree of liver fibrosis progression and a genetic polymorphism near the IL28B gene, the viral factors such as HCV genotype, mutant virus at HCV core region and interferon sensitivity determining region, the treatment factors such as drug adherence and treatment duration have been reported to be associated with SVR. The risk for hepatocellular carcinoma (HCC) incidence was significantly lower in SVR patients than non-SVR patients. Especially, alpha-fetoprotein (AFP) levels decreased through therapy, and the patients with < 5 ng/mL had a low potential of HCC incidence regardless of HCV eradication. It is suggested that AFP levels at 24 weeks after the treatment can be a good surrogate marker for HCC incidence irrespective of the virologic response.
- Published
- 2015
27. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.
- Author
-
Hiramatsu N, Oze T, and Takehara T
- Abstract
The advance of antiviral treatment for chronic hepatitis C has brought a high sustained virological response (SVR) rate. In this review article, the suppressive effect of interferon (IFN)-based therapy on the development of hepatocellular carcinoma (HCC), risk factors for developing HCC and the characteristics of HCC development after SVR among chronic hepatitis C patients given IFN-based therapy were studied. The HCC incidence has been revealed to decrease with IFN-based antiviral therapy, especially in SVR, and the risk factors for developing HCC were older age, advanced liver fibrosis and male sex. α-Fetoprotein levels at 24 weeks after the end of IFN-based treatment was associated strongly with HCC incidence irrespective of virological response. In patients with SVR, other risk factors were glucose metabolism disorders, lipid metabolism disorders and alcohol intake. Extra attention to the possibility of HCC incidence should be required for these SVR patients. Antiviral therapy with a combination of HCV-specific direct-acting antivirals (DAA) is expected to be utilized in the future. However, it is not known whether DAA-based treatment can suppress HCC to the level of IFN-based treatment. Further research is required to clarify this., (© 2014 The Japan Society of Hepatology.)
- Published
- 2015
- Full Text
- View/download PDF
28. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C.
- Author
-
Fukuda K, Imai Y, Hiramatsu N, Irishio K, Igura T, Sawai Y, Kogita S, Makino Y, Mizumoto R, Matsumoto Y, Nakahara M, Zushi S, Kajiwara N, Oze T, Kawata S, Hayashi N, and Takehara T
- Abstract
Aim: Renal damage has been reported as an important complication during combination treatment of peginterferon (PEG IFN), ribavirin (RBV) and telaprevir (TVR) for chronic hepatitis C. However, very little is known about this complication. We investigated the role TVR plays in renal damage during this triple therapy., Methods: Twenty-five chronic hepatitis C patients with genotype 1 and high viral load received TVR in combination with PEG IFN and RBV for 12 weeks followed by treatment with PEG IFN and RBV. Renal function of these patients was prospectively evaluated for 16 weeks., Results: Creatinine clearance decreased significantly during PEG IFN/RBV/TVR treatment. Consequently, serum creatinine and cystatin C significantly rose during PEG IFN/RBV/TVR treatment. Serum creatinine returned to pretreatment levels after the termination of TVR. The increase of serum creatinine and cystatin C from baseline significantly correlated with serum TVR level at day 7, which was determined by starting dose of TVR per bodyweight . When the patients were classified according to the starting dose of TVR per bodyweight, renal impairment was observed only in the high-dose (TVR ≥33 mg/kg per day) group, not in the low-dose (TVR <33 mg/kg per day) group., Conclusion: These results suggest that TVR dose per bodyweight is important for the occurrence of renal impairment in PEG IFN/RBV/TVR treatment., (© 2013 The Japan Society of Hepatology.)
- Published
- 2014
- Full Text
- View/download PDF
29. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, and Takehara T
- Subjects
- Adult, Aged, Female, Humans, Incidence, Interferon-alpha therapeutic use, Japan epidemiology, Male, Middle Aged, Prognosis, Prospective Studies, Ribavirin therapeutic use, Risk Factors, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular epidemiology, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Liver Neoplasms epidemiology, alpha-Fetoproteins analysis
- Abstract
Background & Aims: In patients with chronic hepatitis C virus (HCV) infection, lack of sustained virologic response (SVR) 24 weeks after the end of interferon therapy is a significant risk factor for hepatocellular carcinoma (HCC). Although many pretreatment factors are known to affect HCC incidence, less is known about post-treatment factors-many change during the course of interferon therapy., Methods: We performed a prospective study, collecting data from 2659 patients with chronic hepatitis C without a history of HCC who had been treated with pegylated interferon (Peg-IFN) plus ribavirin from 2002 through 2008 at hospitals in Japan. Biopsy specimens were collected before treatment; all patients received Peg-IFN plus ribavirin for 48 to 72 weeks (HCV genotype 1) or 24 weeks (HCV genotype 2). Hematologic, biochemical, and virologic data were collected every 4 weeks during treatment and every 6 months after treatment. HCC was diagnosed based on angiography, computed tomography, and/or magnetic resonance imaging findings., Results: HCC developed in 104 patients during a mean observation period of 40 months. Older age, male sex, lower platelet counts and higher levels of α-fetoprotein at baseline, and lack of an SVR were significant risk factors for HCC. The cumulative incidence of HCC was significantly lower in patients without SVRs who relapsed than those with no response to treatment. Levels of α-fetoprotein 24 weeks after the end of treatment (AFP24) were significantly lower than levels of α-fetoprotein at baseline in patients with SVRs and those who relapsed, but not in nonresponders. Post-treatment risk factors for HCC among patients with SVRs included higher AFP24 level and older age; among those without SVRs, risk factors included higher AFP24 level, integrated level of alanine aminotransferase, older age, and male sex. AFP24 (≥10 ng/mL, 10-5 ng/mL, and then <5 ng/mL) was a better predictor of HCC incidence than pretreatment level of AFP among patients with and without SVRs., Conclusions: In patients with chronic HCV infection, levels of α-fetoprotein decrease during interferon therapy. High post-treatment levels of α-fetoprotein predict HCC, regardless of whether patients achieve an SVR. University Hospital Medical Information Network Clinical Trials Registry: C000000196, C000000197., (Copyright © 2014. Published by Elsevier Inc.)
- Published
- 2014
- Full Text
- View/download PDF
30. Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis.
- Author
-
Morishita N, Hiramatsu N, Oze T, Harada N, Yamada R, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, and Takehara T
- Subjects
- Aged, Biomarkers blood, Disease Progression, Elasticity Imaging Techniques, Esophageal and Gastric Varices diagnosis, Esophageal and Gastric Varices etiology, Esophagoscopy, Female, Humans, Liver diagnostic imaging, Liver Cirrhosis virology, Male, Middle Aged, Predictive Value of Tests, Reproducibility of Results, Severity of Illness Index, Esophageal and Gastric Varices diagnostic imaging, Hepatitis C, Chronic complications, Liver Cirrhosis complications
- Abstract
Background: Screening and periodic surveillance for esophageal varices (EVs) by esophagogastroduodenoscopy (EGD) are recommended for cirrhotic patients. We investigated non-invasive liver stiffness measurement using acoustic radiation force impulse (ARFI) for the diagnosis of EV presence and high-risk EVs among patients with HCV-related cirrhosis., Methods: Among 181 consecutive patients with HCV-related cirrhosis, we studied 135 patients who had received EGD and ARFI. Serum fibrosis markers [platelet count, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI)] were measured in a training set of 92 patients and compared with ARFI in the diagnostic performance for EV presence and high-risk EVs. Furthermore, the obtained optimal cutoff values of ARFI were prospectively examined in a validation set of 43 patients., Results: In the training set, the ARFI value increased with the EV grade (p < 0.001). The ARFI value for high-risk EVs was significantly higher than that for low-risk EVs (p < 0.001). AUROC values for diagnosis of EV presence and high-risk EVs by ARFI were 0.890 and 0.868, which had the highest diagnostic performance among factors including serum fibrosis markers. The optimal cutoff value of ARFI for EV presence was 2.05 m/s with good sensitivity (83%), specificity (76%), PPV (78%), and NPV (81%), and that for high-risk EVs was 2.39 m/s with good sensitivity (81%), specificity (82%), PPV (69%), and NPV (89%). These cutoff values obtained in the training cohort also showed excellent performance in the validation set., Conclusions: Liver stiffness measurement by ARFI is useful in predicting EV presence or high-risk EVs among patients with HCV-related cirrhosis.
- Published
- 2014
- Full Text
- View/download PDF
31. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, and Takehara T
- Subjects
- Aged, Drug Therapy, Combination, Female, Genotype, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferons, Interleukins genetics, Liver Cirrhosis pathology, Liver Cirrhosis virology, Male, Middle Aged, Polymorphism, Single Nucleotide, Predictive Value of Tests, Recombinant Proteins therapeutic use, Retrospective Studies, Time Factors, Viral Load, Antiviral Agents therapeutic use, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic genetics, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, RNA, Viral blood, Ribavirin therapeutic use
- Abstract
Background: HCV kinetics during treatment demonstrated strong association with the antiviral outcome of patients treated with pegylated interferon (Peg-IFN) plus ribavirin. However, the relationship between HCV kinetics and pre-treatment factors remains unclear., Methods: Of 547 patients with HCV genotype 1 treated with Peg-IFN alfa-2b plus ribavirin, 401 completed the response-guided therapy and were assessed for per protocol analysis., Results: The sustained virologic response (SVR) rate was 53 % for all patients, 60 % for those with genotype TT, and 19 % for those with genotype TG/GG according to IL28B (rs8099917) single nucleotide polymorphisms. The SVR rates increased with HCV decrease at week 4; 4 % (2/56) with <1 log10 decrease, 13 % (7/56) with 1-2 log10 decrease, 51 % (44/87) with 2-3 log10 decrease, 64 % (56/87) with 3-4 log10 decrease, 88 % (72/82) with more than 4 log10 decrease but with detectable HCV RNA and 100 % (33/33) with undetectable HCV RNA (p < 0.001). Similarly, SVR rates increased step-by-step in proportion to HCV decrease in both IL28B TT and TG/GG groups, showing almost the same SVR rates for the same conditions. In multivariate analysis, age (p = 0.005) and the magnitude of HCV decrease at week 4 (p < 0.001) but not IL28B were associated with SVR. Advanced liver fibrosis (p = 0.004) and the magnitude of HCV decrease at week 4 (p < 0.001) but not IL28B were associated with non-response., Conclusions: The magnitude of the HCV decrease at week 4 seems to be the most reliable marker for predicting antiviral outcome after starting Peg-IFN plus ribavirin therapy.
- Published
- 2014
- Full Text
- View/download PDF
32. Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.
- Author
-
Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Hayashi N, and Takehara T
- Subjects
- Adult, Aged, Female, Humans, Interferons therapeutic use, Interleukins genetics, Liver Cirrhosis pathology, Male, Middle Aged, Ribavirin therapeutic use, Treatment Outcome, Antiviral Agents therapeutic use, Drug Monitoring methods, Elasticity Imaging Techniques methods, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic pathology, Liver pathology, Liver Cirrhosis diagnosis
- Abstract
The degree of liver fibrosis is strongly associated with the antiviral effect of interferon on chronic hepatitis C patients. In this study, the accuracy of acoustic radiation force impulse (ARFI) in assessing liver fibrosis and the association between liver stiffness using ARFI and antiviral effects were investigated. The 124 patients with chronic hepatitis C enrolled in this study included 94 with HCV genotype 1 and 40 (30%) with moderate fibrosis (METAVIR fibrosis score ≥ F2). Sixty-one patients received pegylated interferon (peg-IFN) plus ribavirin combination therapy and the treatment responses were assessed. The shear wave velocity (Vs value) by ARFI had a strong correlation with the histological fibrosis stage (P < 0.001). The AUROC of the Vs value, aspartate aminotransferase platelet ratio index and FIB4 for the diagnoses of moderate fibrosis (≥F2) were 0.890, 0.779, and 0.737, respectively. HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (≥1.40 m/sec) experienced a non-virologic response (6/6). The Vs value measured by ARFI could not predict the treatment response for patients with HCV genotype 2. It is concluded that the combination of ARFI at cut off of 1.4 m/sec and IL28B may be useful for patients with chronic hepatitis C with genotype 1 treated with peg-IFN/ribavirin combination therapy., (© 2013 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
33. Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.
- Author
-
Higashitani K, Kanto T, Kuroda S, Yoshio S, Matsubara T, Kakita N, Oze T, Miyazaki M, Sakakibara M, Hiramatsu N, Mita E, Imai Y, Kasahara A, Okuno A, Takikawa O, Hayashi N, and Takehara T
- Subjects
- Adult, Female, Humans, Male, Dendritic Cells enzymology, Hepatitis C, Chronic enzymology, Hepatitis C, Chronic immunology, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, T-Lymphocytes, Regulatory physiology
- Abstract
Background: Altered functions of dendritic cells (DCs) and/or increases of regulatory T cells (Tregs) are involved in the pathogenesis of chronic hepatitis C virus (HCV) infection. A tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase (IDO), is reported to be an inducer of immune tolerance. Our aim was to clarify whether or not IDO is activated in chronic hepatitis C patients and its role in immune responses., Methods: This study enrolled 176 patients with chronic HCV infection and 37 healthy volunteers. Serum kynurenine concentration was evaluated by high-performance liquid chromatography, and its correlation with clinical parameters was examined. Monocyte-derived DCs were prepared from the subjects and subsequently stimulated with a combination of lipopolysaccharide and interferon-gamma to induce functional IDO (defined as IDO-DCs). The phenotypes, kynurenine or cytokine production, and T-cell responses with IDO-DCs were compared between the patients and healthy volunteers., Results: The serum kynurenine level in the patients was significantly higher than that in the healthy volunteers, and the level of serum kynurenine was positively correlated with the histological activity or fibrosis score. IDO activity in IDO-DCs from the patients was significantly higher than that in IDO-DCs from the volunteers. Furthermore, IDO-DCs from the patients induced more Tregs in vitro compared with those from the volunteers, and the frequency of induced Tregs by IDO-DCs was decreased with an IDO-specific inhibitor., Conclusions: Systemic IDO activity is enhanced in chronic hepatitis C patients in correlation with the degree of liver inflammation and fibrosis. In response to inflammatory stimuli, DCs from the patients tend to induce Tregs, with some of this action being dependent on IDO.
- Published
- 2013
- Full Text
- View/download PDF
34. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
- Author
-
Harada N, Hiramatsu N, Oze T, Yamada R, Kurokawa M, Miyazaki M, Yakushijin T, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, and Takehara T
- Subjects
- Adult, Aged, Antiviral Agents therapeutic use, Biomarkers blood, Carcinoma, Hepatocellular epidemiology, Clinical Enzyme Tests methods, Clinical Enzyme Tests standards, Drug Therapy, Combination, Female, Hepatitis C, Chronic blood, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic epidemiology, Humans, Incidence, Interferon alpha-2, Interferon-alpha therapeutic use, Japan epidemiology, Liver Neoplasms epidemiology, Male, Middle Aged, Patient Selection, Platelet Count, Polyethylene Glycols therapeutic use, Recombinant Proteins therapeutic use, Retrospective Studies, Ribavirin therapeutic use, Severity of Illness Index, Treatment Outcome, Alanine Transaminase blood, Carcinoma, Hepatocellular virology, Hepatitis C, Chronic complications, Liver Neoplasms virology, Practice Guidelines as Topic
- Abstract
Background: This study was conducted to evaluate Japanese treatment guidelines for patients with chronic hepatitis C virus (HCV) infection and normal alanine aminotransferase (N-ALT) levels from the viewpoint of the incidence of hepatocellular carcinoma (HCC)., Methods: Four groups of patients with chronic HCV infection treated with pegylated interferon (Peg-IFN) plus ribavirin, and classified according to the N-ALT guidelines, were examined for HCC incidence: group A (n = 353), ALT ≤30 IU/L and platelet (PLT) ≥15 × 10(4)/mm(3); group B (n = 123), ALT ≤30 IU/L and PLT <15 × 10(4)/mm(3); group C (n = 233), 30 < ALT ≤ 40 IU/L and PLT ≥15 × 10(4)/mm(3); and group D (n = 100), 30 < ALT ≤ 40 IU/L and PLT <15 × 10(4)/mm(3). The mean observation period was 36.2 ± 16.5 months, Results: In groups A and C, the HCC incidence was low even in patients with non-response (NR) (cumulative rates at 3 years, 0.0 and 2.9 %, respectively). In groups B and D, 14.5 and 5.3 % of NR patients had developed HCC at 3 years, but none of the patients with sustained virologic response (SVR) or relapse had developed HCC. In group B, no patients with mild fibrosis developed HCC irrespective of the antiviral effect of the treatment. Among patients with PLT <15 × 10(4)/mm(3) (group B plus group D), the HCC incidence was significantly lower in patients with SVR and relapse than in NR patients (p < 0.001, p = 0.021, respectively)., Conclusion: These results suggest that N-ALT patients with PLT <15 × 10(4)/mm(3) could be candidates for early antiviral therapy.
- Published
- 2013
- Full Text
- View/download PDF
35. A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
- Author
-
Oze T, Hiramatsu N, Mita E, Akuta N, Sakamoto N, Nagano H, Itoh Y, Kaneko S, Izumi N, Nomura H, Hayashi N, and Takehara T
- Abstract
Aim: This study aimed to clarify the factors associated the efficacy of re-treatment with pegylated interferon (PEG IFN) plus ribavirin combination therapy for patients with chronic hepatitis C who had failed to respond to previous treatment., Methods: One hundred and forty-three patients who had previously shown relapse (n = 79), non-response (n = 34) or intolerance (n = 30) to PEG IFN plus ribavirin were re-treated with PEG IFN plus ribavirin., Results: Twenty-five patients with intolerance to previous treatment completed re-treatment and the sustained virological response (SVR) rates were 55% and 80% for hepatitis C virus (HCV) genotype 1 and 2, respectively. On re-treatment of the 113 patients who completed the previous treatment, the SVR rates were 48% and 63% for genotype 1 and 2, respectively. Relapse after previous treatment and a low baseline HCV RNA level on re-treatment were associated with SVR in genotype 1 (P < 0.001). Patients with the interleukin-28B major genotype responded significantly better and earlier to re-treatment, but the difference in the SVR rate did not reach a significant level between the major and minor genotypes (P = 0.09). Extended treatment of 72 weeks raised the SVR rate among the patients who attained complete early virological response but not rapid virological response with re-treatment (72 weeks, 73%, 16/22, vs 48 weeks, 38%, 5/13, P < 0.05)., Conclusion: Relapse after previous treatment and a low baseline HCV RNA level have predictive values for a favorable response of PEG IFN plus ribavirin re-treatment for HCV genotype 1 patients. Re-treatment for 72 weeks may lead to clinical improvement for genotype 1 patients with complete early virological response and without rapid virological response on re-treatment., (© 2012 The Japan Society of Hepatology.)
- Published
- 2013
- Full Text
- View/download PDF
36. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma.
- Author
-
Kohga K, Tatsumi T, Tsunematsu H, Aono S, Shimizu S, Kodama T, Hikita H, Yamamoto M, Oze T, Aketa H, Hosui A, Miyagi T, Ishida H, Hiramatsu N, Kanto T, Hayashi N, and Takehara T
- Subjects
- ADAM Proteins biosynthesis, ADAM Proteins immunology, Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Female, Hep G2 Cells, Hepatocytes drug effects, Hepatocytes immunology, Hepatocytes metabolism, Humans, Interleukin-1beta blood, Killer Cells, Natural immunology, Liver Neoplasms blood, Liver Neoplasms pathology, Male, Membrane Proteins biosynthesis, Membrane Proteins immunology, Middle Aged, Carcinoma, Hepatocellular immunology, Histocompatibility Antigens Class I biosynthesis, Interleukin-1beta immunology, Interleukin-1beta pharmacology, Liver Neoplasms immunology
- Abstract
The production of soluble major histocompatibility complex class I-related chain A (MICA) is thought to antagonize NKG2D-mediated immunosurveillance. Interleukin-1β (IL-1β) is elevated in patients with chronic hepatitis C (CH), and this might contribute to the escape of hepatocellular carcinoma (HCC) cells from innate immunity. In this study, we investigated the immunoregulatory role of IL-1β in the production of soluble MICA of HCC cells. First, we investigated the correlation between the serum IL-1β levels and soluble MICA in CH patients. Serum IL-1β levels were associated with soluble MICA levels in CH patients. The serum IL-1β levels of CH patients with the HCC occurrence were significantly higher than those of CH patients without HCC. We next examined the MICA production of IL-1β-treated HCC cells. Addition of IL-1β resulted in significant increase in the production of soluble MICA in HepG2 and PLC/PRF/5 cells, human HCC cells. But soluble MICA was not detected in both non-treated and IL-1β-treated normal hepatocytes. Addition of IL-1β did not increase the expressions of membrane-bound MICA on HCC cells. These were observed similarly in various cancer cells including a gastric cancer (MKN1), two colon cancers (HCT116 and HT29) and a cervical cancer (HeLa). Addition of IL-1β also increased the expression of a disintegrin and metalloproteinase (ADAM)9 in HCC cells, and the knockdown of ADAM9 in IL-1β-treated HCC cells resulted in the decrease in the production of soluble MICA of HCC cells. These findings indicate that IL-1β might enhance the production of soluble MICA by activating ADAM9 in human HCC.
- Published
- 2012
- Full Text
- View/download PDF
37. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
- Author
-
Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, and Takehara T
- Subjects
- Adult, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular virology, DNA, Viral blood, Female, Hepatitis B virus isolation & purification, Hepatitis B, Chronic complications, Hepatitis B, Chronic epidemiology, Hepatitis B, Chronic virology, Humans, Incidence, Japan epidemiology, Liver Neoplasms epidemiology, Liver Neoplasms virology, Male, Middle Aged, Risk Factors, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular prevention & control, Hepatitis B, Chronic drug therapy, Lamivudine therapeutic use, Liver Neoplasms prevention & control
- Abstract
Background: Nucleotide analogues have recently been approved for the treatment of patients with hepatitis B virus (HBV) infection. However, it is still controversial whether the decrease of HBV-DNA amount induced by treatment with nucleotide analogues can reduce the risk of hepatocellular carcinoma (HCC) development in HBV patients., Methods: A total of 293 HBV patients without HCC who were treated with lamivudine (LAM) were enrolled in a multicenter trial. The incidence of HCC was examined after the start of LAM therapy, and the risk factors for liver carcinogenesis were analyzed. The mean follow-up period was 67.6 ± 27.4 months., Results: On multivariate analysis for HCC development in all patients, age ≥50 years, platelet count <14.0 × 10(4)/mm(3), cirrhosis, and median HBV-DNA levels of ≥4.0 log copies/ml during LAM treatment were significant risk factors. The cumulative carcinogenesis rate at 5 years was 3% in patients with chronic hepatitis and 30% in those with cirrhosis. For the chronic hepatitis patients, the log-rank test showed the significant risk factors related to HCC development to be age ≥50 years, platelet count <14.0 × 10(4)/mm(3), and hepatitis B e antigen negativity, but median HBV-DNA levels of <4.0 log copies/ml (maintained viral response, MVR) did not significantly suppress the development of HCC. In cirrhosis patients, however, the attainment of MVR during LAM treatment was revealed to reduce the risk of HCC development., Conclusions: These results suggest that the incidence of HCC in HBV patients with cirrhosis can be reduced in those with an MVR induced by consecutive LAM treatment.
- Published
- 2012
- Full Text
- View/download PDF
38. Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.
- Author
-
Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Hayashi N, and Takehara T
- Subjects
- Adult, Aged, Antiviral Agents administration & dosage, Cohort Studies, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Hepacivirus isolation & purification, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Male, Middle Aged, Polyethylene Glycols administration & dosage, Propensity Score, Recombinant Proteins administration & dosage, Recombinant Proteins therapeutic use, Retrospective Studies, Ribavirin administration & dosage, Time Factors, Treatment Failure, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
Background: The timing to the first undetectable hepatitis C virus (HCV) RNA level is strongly associated with sustained virologic response in pegylated interferon (Peg-IFN) plus ribavirin combination therapy for patients with chronic hepatitis C (CH-C) with genotype 1. This study was conducted to clarify the impact of drug exposure to Peg-IFN on the timing of HCV RNA negativity in Peg-IFN plus ribavirin combination therapy for CH-C patients with genotype 1., Methods: A total of 1409 patients treated with Peg-IFN alfa-2b plus ribavirin were enrolled and classified into four categories according to the Peg-IFN dosage. Furthermore, 100 patients were extracted from each Peg-IFN dosage category to adjust for characteristic factors, using the propensity score method., Results: Peg-IFN exposure was dose-dependently associated with the timing of HCV RNA negativity (p ≤ 0.001). The HCV RNA negative rate at week 4 decreased from 12% with a Peg-IFN dose of >1.5 μg/kg/week to 1-3% with a dose of <1.5 μg/kg/week (p ≤ 0.001), and at week 12 the rate had decreased from 44% with a dose of ≥1.2 μg/kg/week to 18% with a dose of <1.2 μg/kg/week (p = 0.001). Treatment failure (patients without a 1-log decrease of HCV RNA at week 4 or a 2-log decrease of HCV RNA at week 12, or positive at week 24) was found in 54-66% of patients given <1.2 μg/kg/week (p ≤ 0.001), and these patients accounted for 64% of the non-responders., Conclusions: The timing of HCV RNA negativity depends significantly on the Peg-IFN dose. Reducing the Peg-IFN dose can induce a later virologic response or non-response in HCV genotype 1 patients treated with Peg-IFN plus ribavirin.
- Published
- 2012
- Full Text
- View/download PDF
39. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
- Author
-
Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, and Hayashi N
- Subjects
- Adult, Aged, Alanine Transaminase drug effects, Case-Control Studies, Drug Therapy, Combination, Female, Genotype, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C, Chronic blood, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Male, Middle Aged, Prognosis, Propensity Score, RNA, Viral blood, Recombinant Proteins administration & dosage, Treatment Outcome, Viral Load, Alanine Transaminase blood, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Polyethylene Glycols administration & dosage, Ribavirin administration & dosage
- Abstract
Background: The antiviral effect of pegylated interferon (Peg-IFN) plus ribavirin combination therapy in chronic hepatitis C (CHC) patients with normal alanine aminotransferase (ALT) levels (N-ALT) has been reported to be equivalent to that for patients with elevated ALT levels (E-ALT). However, the actual antiviral effect in N-ALT patients remains obscure because efficacy can be overestimated in patients with an advantageous background., Methods: In this study, 386 patients were extracted, for a matched case-control study, from 1320 CHC patients treated with Peg-IFN alpha-2b plus ribavirin combination therapy; 193 N-ALT patients [116 with hepatitis C virus genotype 1 (HCV-1), 77 with HCV genotype 2 (HCV-2)] were matched with 193 E-ALT patients by a propensity score method using the variables of age, sex, IFN treatment history, body mass index, and platelet counts., Results: On multivariate analysis for sustained virological response (SVR) in N-ALT patients, younger age, low HCV RNA level at baseline, and HCV-2 were significant factors. The matched case-control study showed that the SVR rates of N-ALT patients were equivalent to those of E-ALT patients; at 49 and 40% in the HCV-1 group (P = 0.146), and 78 and 81% in the HCV-2 group (P = 0.691). However, in N-ALT patients with non-SVR, approximately 40% showed ALT elevation at 24 weeks post-treatment., Conclusion: Our findings indicate that the antiviral effect of Peg-IFN plus ribavirin therapy in N-ALT patients is comparable to that for E-ALT patients irrespective of their advantageous background; however, the application of this therapy for N-ALT patients, especially for those with HCV-1, should be considered carefully.
- Published
- 2011
- Full Text
- View/download PDF
40. Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Hosui A, Miyagi T, Ishida H, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N
- Subjects
- Antiviral Agents administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, Hepacivirus isolation & purification, Hepatitis C, Chronic genetics, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Japan, Male, Middle Aged, Polyethylene Glycols administration & dosage, RNA, Viral blood, Recombinant Proteins administration & dosage, Recombinant Proteins therapeutic use, Retreatment, Retrospective Studies, Ribavirin administration & dosage, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
Background: It is still not known which patients with chronic hepatitis C who failed to respond to previous pegylated interferon (Peg-IFN) plus ribavirin therapy can benefit from re-treatment., Methods: Seventy-four patients (HCV genotype 1, n = 56, genotype 2, n = 18) were re-treated with Peg-IFN plus ribavirin., Results: On re-treatment, the sustained virologic response (SVR) rate was 41% for genotype 1 and 56% for genotype 2. With genotype 1, the factors associated with an SVR were previous treatment response and the serum hepatitis C virus (HCV) RNA level at the start of re-treatment. Patients with a ≥ 2-log decrease in HCV RNA at week 12 (partial early virologic response, p-EVR) in previous treatment had significantly higher SVR rates than those without these decreases (p < 0.001); no patient without a p-EVR in the previous treatment attained an SVR with re-treatment (0/16). All patients with <5 log(10) IU/ml of HCV RNA at the start of re-treatment attained an SVR (6/6), while only 33% (15/45) of those patients with ≥ 5 log(10) IU/ml of HCV RNA attained an SVR (p < 0.01). Among the patients with relapse in the previous treatment, those who attained an SVR on re-treatment required a longer duration of re-treatment than the duration of the previous treatment (re-treatment, 63.8 ± 13.0 weeks vs. previous treatment, 53.9 ± 13.5 weeks, p = 0.01)., Conclusions: Re-treatment of genotype 1 patients should be limited to patients with a p-EVR in the previous treatment and a low HCV RNA level at the start of re-treatment. In re-treatment with Peg-IFN plus ribavirin, longer treatment duration can contribute to increasing the anti-viral effect.
- Published
- 2011
- Full Text
- View/download PDF
41. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Nagase T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N
- Subjects
- Aged, Antiviral Agents administration & dosage, Case-Control Studies, Drug Therapy, Combination, Female, Genotype, Humans, Interferon alpha-2, Japan, Male, Middle Aged, RNA, Viral blood, Recombinant Proteins, Retrospective Studies, Treatment Outcome, Viral Load, Hepatitis C genetics, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Polyethylene Glycols administration & dosage, Ribavirin administration & dosage
- Abstract
Background: Which patients with hepatitis C virus (HCV) genotype 1 can benefit from extended treatment with pegylated interferon (Peg-IFN) plus ribavirin is unknown, although the overall sustained virologic response (SVR) rate has been shown to improve in patients with a late virologic response (LVR), defined as detectable serum HCV RNA at week 12 and undetectable at week 24., Methods: Among 1163 chronic hepatitis C patients with genotype 1 treated with Peg-IFN plus ribavirin combination therapy, 213 patients with an LVR were examined in this study. In addition, we selected 81 patients of matched sex and age from each of the 48- and 72-week treatment groups, using the propensity score, to compare the efficacy of the two treatment durations., Results: With 72-week treatment, the timing of HCV RNA disappearance and the hemoglobin level at baseline showed a strong correlation with the SVR on multivariate analysis. Earlier HCV RNA disappearance was associated with a better SVR rate, regardless of the ribavirin dose (HCV RNA disappearance at week 16, 74%; at week 20, 52%; and at week 24, 31%, p = 0.01). The SVR rate with 72-week treatment was higher than that with 48-week treatment, irrespective of age, sex, or the platelet value, and, especially in aged patients (≥65 years old), the SVR rate increased markedly with 72-week treatment (48 weeks, 25% vs. 72 weeks, 56%; p < 0.05)., Conclusions: An earlier response predicts a higher SVR rate in patients with an LVR given 72-week treatment. Extended treatment with Peg-IFN plus ribavirin for patients with an LVR improved the treatment efficacy, even for aged patients.
- Published
- 2011
- Full Text
- View/download PDF
42. [Development of anti viral therapy for chronic hepatitis type C].
- Author
-
Hayashi N, Oze T, and Hiramatsu N
- Subjects
- Drug Therapy, Combination, Genotype, Hepatitis C, Chronic genetics, Humans, Interferons administration & dosage, Recombinant Proteins administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Polyethylene Glycols administration & dosage, Ribavirin administration & dosage
- Published
- 2011
43. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Kaytayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N
- Subjects
- Adult, Age Factors, Aged, Antiviral Agents adverse effects, Cohort Studies, Drug Therapy, Combination, Female, Genotype, Hepacivirus classification, Hepacivirus genetics, Hepatitis C, Chronic virology, Humans, Interferon alpha-2, Interferon-alpha adverse effects, Male, Middle Aged, Polyethylene Glycols adverse effects, RNA, Viral blood, Recombinant Proteins, Retrospective Studies, Ribavirin adverse effects, Treatment Outcome, Antiviral Agents administration & dosage, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Polyethylene Glycols administration & dosage, Ribavirin administration & dosage
- Abstract
Background & Aims: This study investigated the efficacy and adverse effects of pegylated interferon (Peg-IFN) plus ribavirin therapy in aged patients with chronic hepatitis C (CH-C)., Methods: A total of 1040 naïve patients with CH-C (genotype 1, n=759; genotype 2, n=281), of whom 240 (23%) over 65 years old (y.o.), were treated with Peg-IFN alfa-2b plus ribavirin and assessed after being classified into five categories, according to age., Results: The discontinuance rate was higher for patients over 70 y.o. (36%), the most common reason being anemia. In the presence of genotype 1, the SVR rate was similar (42-46%) among patients under 65 y.o. and declined (26-29%) among patients over 65 y.o. For patients over 65 y.o., being male (Odds ratio, OR, 3.5, p=0.035) and EVR (OR, 83.3, p<0.001) were significant factors for SVR, in multivariate analysis. The Peg-IFN dose was related to EVR, and when EVR was attained, 76-86% of patients over 65 y.o. achieved SVR. SVR was not achieved (0/35, 0/38, respectively) if a 1-log decrease and a 2-log decrease were not attained at week 4 and week 8, respectively. In the presence of genotype 2, the SVR rate was similar (70-71%) among patients under 70 y.o. and declined among patients over 70 y.o. (43%)., Conclusions: Aged patients up to 65 y.o. with genotype 1 and 70 y.o. with genotype 2 can be candidates for Peg-IFN plus ribavirin therapy. The response-guided therapy can be applied for aged patients with genotype 1., (Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
44. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
- Author
-
Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, Mita E, Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N
- Subjects
- Adult, Aged, Antiviral Agents therapeutic use, Disease Progression, Drug Therapy, Combination, Female, Genotype, Humans, Interferon alpha-2, Male, Middle Aged, Mutation, RNA, Viral blood, Recombinant Proteins therapeutic use, Recurrence, Retrospective Studies, Treatment Outcome, Viral Load, Amino Acid Substitution, Hepacivirus genetics, Hepatitis C drug therapy, Hepatitis C genetics, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use, Viral Core Proteins chemistry, Viral Core Proteins genetics
- Abstract
Previous reports demonstrated that amino acid (aa) substitutions in the hepatitis C virus (HCV) core protein are predictors of non-virological responses to pegylated interferon (Peg-IFN) and ribavirin combination therapy. The aim of this study was to investigate the impact of core aa substitutions on viral kinetics during the treatment and relapse after the treatment. The 187 patients with HCV genotype 1 enrolled in this study were categorized into four groups according to core aa substitution patterns: double-wild group (n=92), Arg70/Leu91; 70-mutant group (n=42), Gln70/Leu91; 91-mutant group (n=31), Arg70/Met91; and double-mutant group (n=22), Gln70/Met91. The relationship between the core aa substitutions and the virological response was examined. Multivariate logistic regression analyses showed that substitution at aa 70 was significantly associated with a poor virological response during the first 12 weeks (decline of <1 log from baseline at week 4, <2 log at week 12), and substitution at aa 91 was significantly associated with detectable HCV RNA at week 24. With respect to relapse, only the ribavirin exposure (odds ratio (OR), 0.77; 95% confidence interval (CI), 0.60-0.98) and HCV RNA disappearance between weeks 13 and 24 (OR, 23.69; 95% CI, 5.44-103.08) were associated independently with relapse, with no correlation being found with the core aa substitutions and relapse. In conclusion, the results showed that core aa substitutions can be strong predictive factors at pretreatment of the non-response, but not for relapse, for virological responders with HCV RNA disappearance during treatment., (Copyright © 2011 Wiley-Liss, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
45. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
- Author
-
Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N
- Subjects
- Aged, Dose-Response Relationship, Drug, Female, Genotype, Hepacivirus genetics, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Male, Middle Aged, Polyethylene Glycols administration & dosage, RNA, Viral blood, Recombinant Proteins, Treatment Outcome, Antiviral Agents therapeutic use, Hepacivirus isolation & purification, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
Chronic hepatitis C (CH-C) genotype 1 patients who achieved early virologic response have a high probability of sustained virologic response (SVR) following pegylated interferon (Peg-IFN) plus ribavirin therapy. This study was conducted to evaluate how reducing drug doses affects complete early virologic response (c-EVR) defined as hepatitis C virus (HCV) RNA negativity at week 12. Nine hundred eighty-four patients with CH-C genotype 1 were enrolled. Drug doses were evaluated independently on a body weight base from doses actually taken. From multivariate analysis, the mean dose of Peg-IFN alpha-2b during the first 12 weeks was the independent factor for c-EVR (P = 0.02), not ribavirin. The c-EVR rate was 55% in patients receiving > or = 1.2 microg/kg/week of Peg-IFN, and declined to 38% at 0.9-1.2 microg/kg/week, and 22% in patients given <0.9 microg/kg/week (P < 0.0001). Even with stratified analysis according to ribavirin dose, the dose-dependent effect of Peg-IFN on c-EVR was observed, and similar c-EVR rates were obtained if the dose categories of Peg-IFN were the same. Furthermore, the mean dose of Peg-IFN during the first 12 weeks affected HCV RNA negativity at week 24 (P < 0.0001) and SVR (P < 0.0001) in a dose-dependent manner. Our results suggest that Peg-IFN was dose-dependently correlated with c-EVR, independently of ribavirin dose. Thus, maintaining the Peg-IFN dose as high as possible during the first 12 weeks can yield HCV RNA negativity and higher c-EVR rates, leading to better SVR rates in patients with CH-C genotype 1.
- Published
- 2009
- Full Text
- View/download PDF
46. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.
- Author
-
Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, and Hayashi N
- Abstract
Aim: The objective of this study was to elucidate the long-term effects of interferon (IFN)alpha-2b plus ribavirin combination therapy and to clarify whether this therapy can reduce the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C., Methods: A total of 403 patients infected with hepatitis C virus (HCV) were enrolled in a multicenter trial. All patients were treated with a combination of IFN-alpha-2b plus ribavirin therapy. We examined the incidence of HCC after combination therapy and analyzed the risk factors for liver carcinogenesis., Results: A sustained virological response (SVR) was achieved by 139 (34%) of the patients. The cumulative rate of incidence of HCC was significantly lower in SVR patients than in non-SVR patients (P = 0.03), while there was no difference in the cumulative incidence of HCC between the transient response (TR) group and the no response (NR) group. Cox's regression analysis indicated the following risk factors as independently significant in relation to the development of HCC: age being > 60 years (P = 0.006), advanced histological staging (P = 0.033), non-SVR to IFN therapy (P = 0.044). The cumulative incidence rate of HCC was significantly lower in patients who had average serum alanine aminotransferase (ALT) levels of < 40 IU/L than in those who showed average serum ALT levels of >== 40 IU/L after the combination therapy (P = 0.021)., Conclusions: These results suggest that the attainment of SVR or continuous normalization of ALT levels after IFN therapy can affect patients apart from HCC development.
- Published
- 2009
- Full Text
- View/download PDF
47. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.
- Author
-
Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, and Hayashi N
- Subjects
- Adult, Aged, DNA, Viral blood, Drug Resistance, Viral, Female, Follow-Up Studies, Guanine therapeutic use, Hepatitis B virus drug effects, Humans, Male, Middle Aged, Polymerase Chain Reaction, Sequence Analysis, DNA, Antiviral Agents therapeutic use, Guanine analogs & derivatives, Hepatitis B, Chronic drug therapy, Lamivudine therapeutic use
- Abstract
Purpose: A considerable number of chronic hepatitis B (CH-B) patients remain under continuous lamivudine treatment, although switching treatment to entecavir could be beneficial. We investigated the antiviral efficacy of switching treatment to entecavir in CH-B patients without apparent evidence of lamivudine resistance during the preceding lamivudine treatment., Methods: Forty-four CH-B patients, who underwent lamivudine treatment for more than 6 months and showed no evidence of lamivudine resistance, switched to entecavir. Serial changes in hepatitis B virus (HBV) DNA were correlated with the patients' baseline HBV DNA at the commencement of entecavir administration. The entecavir-resistant substitution was examined by PCR-direct sequencing. The median follow-up period of entecavir treatment was 20 (10-23) months., Results: All 31 patients with baseline HBV DNA <2.6 logcopies/ml maintained HBV DNA-negative status during entecavir treatment. Of seven patients having HBV DNA of 2.6-<4.0 logcopies/ml, all achieved undetectable HBV DNA at the end of follow-up. As for six patients having HBV DNA >or=4.0 logcopies/ml, three patients achieved undetectable HBV DNA, whereas virological breakthrough was observed in one patient at month 15. An entecavir-resistant virus having rtM204V, rtL180M and rtS202G substitutions was detected in this patient., Conclusions: The lamivudine-to-entecavir switching treatment may be generally recommendable in CH-B patients without evidence of lamivudine resistance during the preceding lamivudine treatment. However, great care should be taken with respect to the emergence of entecavir-resistance, especially in patients who do not respond well to the preceding lamivudine treatment.
- Published
- 2009
- Full Text
- View/download PDF
48. Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir.
- Author
-
Kurashige N, Ohkawa K, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hosui A, Miyagi T, Ishida H, Tatsumi T, Kanto T, Takehara T, and Hayashi N
- Subjects
- Adenine administration & dosage, Adenine pharmacology, Antiviral Agents administration & dosage, Antiviral Agents pharmacology, Drug Therapy, Combination, Guanine administration & dosage, Guanine pharmacology, Humans, Male, Middle Aged, Adenine analogs & derivatives, Guanine analogs & derivatives, Hepatitis B drug therapy, Hepatitis B virus drug effects, Organophosphonates administration & dosage, Organophosphonates pharmacology
- Abstract
The most serious problem of nucleoside/nucleotide analogue therapy for hepatitis B virus (HBV) infection is the emergence of drug-resistant mutant virus. Here, we describe a patient with chronic hepatitis B infection with a complex drug-resistant mutant virus during sequential therapy with lamivudine (3TC), entecavir (ETV) and adefovir dipivoxil (ADV). The patient was a 52-year-old male with positive hepatitis B e antigen and high HBV DNA (>7.6 log(10) copies/ml). Initial 3TC monotherapy offered little benefit and 3TC resistance was established by the virus with rtA181T and not rtM204V/I. HBV DNA was reduced slightly by replacement with ETV monotherapy and was followed by virological breakthrough. At that time, rtA181T was undetectable and the virus with rtM204V and rtL180M became predominant. ETV resistance was established by an additional rtS202G mutation. Efficacy of subsequent combination therapy with ADV and 3TC was limited because of reappearance of the virus with rtA181T, which might confer cross-resistance to 3TC and ADV. Final combination therapy with ETV and ADV reduced HBV DNA to 3.7 log(10) copies/ml for 5 months, which was the most effective therapy for this patient. Thus, two kinds of mutant viruses (rtM204V-related and rtA181T-related) appeared alternately in this patient. Combination therapy with ETV and ADV might have been effective because these drugs share therapeutic roles, that is, ETV affects the rtA181T-related virus and ADV affects the rtM204V-related virus. This is the first report suggesting clinical significance of combination therapy with ETV and ADV for controlling replication of the complex drug-resistant mutant HBV.
- Published
- 2009
- Full Text
- View/download PDF
49. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine.
- Author
-
Kurashige N, Hiramatsu N, Ohkawa K, Oze T, Inoue Y, Kurokawa M, Yakushijin T, Igura T, Kiso S, Kanto T, Takehara T, Tamura S, Kasahara A, Oshita M, Hijioka T, Katayama K, Yoshihara H, Hayashi E, Imai Y, Kato M, and Hayashi N
- Abstract
Aim: Lamivudine (LAM) has been widely used to treat chronic hepatitis B (CHB) patients, but the emergence of a LAM-resistant virus greatly limits its therapeutic efficacy. In this study, we tried to identify factors affecting the emergence of a LAM-resistant virus in CHB patients treated with LAM., Methods: The subjects were 190 CHB patients in continuous LAM therapy (139 males, mean age 50 years, 87 HBeAg-positive). The mean duration of follow-up was 39 months (range 12-104). The initial viral response (IVR) was defined as HBV DNA < 4.0 logcopies/mL, and the initial biochemical response (IBR) as normalization of alanine aminotransferase (ALT) (<40 IU/L) at 6 months., Results: IVR was positive in 86% of the patients. The cumulative emergence rates of LAM-resistant virus were 10% at 1 year, 30% at 2 years and 46% at 3 years. In univariate analysis, factors contributing to the emergence of LAM-resistant virus were baseline HBV DNA > 6.5 logcopies/mL (P = 0.0044), HBeAg-positivity (P = 0.0062), IBR (P = 0.01) and IVR (P < 0.0001). The cumulative emergence rates of LAM-resistant virus in IVR-positive and -negative patients were 4% and 41% at 1 year, and 41% and 79% at 3 years. In multivariate analysis, only IVR was an independent factor affecting the emergence of LAM-resistant virus (P < 0.0001)., Conclusion: IVR is a useful factor for predicting the emergence of LAM-resistant virus in CHB patients treated with LAM. For IVR-negative patients, therapeutic options other than LAM monotherapy should be used because of the high incidence of the emergence of LAM-resistant virus.
- Published
- 2008
- Full Text
- View/download PDF
50. [Development of antiviral therapy for patients with chronic hepatitis C].
- Author
-
Hayashi N, Oze T, and Hiramatsu N
- Subjects
- Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Interferons therapeutic use, Polyethylene Glycols administration & dosage, Recombinant Proteins, Ribavirin administration & dosage, Viral Nonstructural Proteins antagonists & inhibitors, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.